ASCO 2023 | Cabozantinib with checkpoint inhibition in soft tissue sarcoma

Brian Van Tine, MD, PhD, Washington University, St. Louis, MO, discusses findings from a Phase II trial (NCT04551430) of cabozantinib with nivolumab and ipilimumab in patients with metastatic soft tissue sarcoma. Patients were randomized to receive cabozantinib, nivolumab and ipilimumab, or cabozantinib alone, where crossover was possible. Progression free survival and disease control rate were both superior in patients receiving cabozantinib with immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.